C6orf191 Inhibitors
Chemical inhibitors of C6orf191 function through various mechanisms to modulate signaling pathways that the protein may rely on for its activity. Triciribine acts by specifically targeting the AKT signaling pathway, which is crucial for many cellular processes. By inhibiting AKT, triciribine can reduce phosphorylation of downstream proteins, potentially diminishing the function of C6orf191. LY294002 and Wortmannin are both inhibitors of PI3K, a kinase upstream of AKT in the signaling cascade. Inhibition of PI3K by these chemicals leads to a blockade of the PI3K/AKT pathway, which can decrease C6orf191 activity if it is dependent on this particular pathway for activation or localization. Rapamycin targets the mTOR pathway, which is a central regulator of cell growth and survival.
Further, PD98059 and U0126 inhibit the MEK1/2 enzymes, and through this action, disrupt the MAPK/ERK pathway. The inhibition of this pathway can lead to a reduction in C6orf191 activity if it is regulated by MAPK signaling. SB203580 and SP600125 specifically inhibit the p38 MAPK and JNK pathways, respectively. If C6orf191 relies on p38 MAPK or JNK for its activity, these inhibitors would impede its function. PP2 and Dasatinib, both tyrosine kinase inhibitors, can also affect C6orf191 function if it relies on signaling through Src family kinases. Go6983 and Bisindolylmaleimide I target protein kinase C (PKC) isoforms. If C6orf191 requires PKC for activation, the use of Go6983 or Bisindolylmaleimide I can result in reduced activity of the protein. Through these diverse mechanisms, these chemical inhibitors can alter the functional state of C6orf191 by targeting various points of regulation within cellular signaling networks.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
This chemical specifically inhibits the AKT signaling pathway. Inhibition of AKT can reduce the phosphorylation of downstream proteins, including C6orf191, which may rely on AKT-mediated phosphorylation for its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. By inhibiting PI3K, it blocks the PI3K/AKT pathway, possibly reducing the activity of C6orf191 if its function is dependent on this pathway for membrane localization or other activation processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin irreversibly inhibits PI3K, which can lead to a decrease in AKT activation. If C6orf191 activity is contingent upon AKT signaling, this inhibition would result in decreased function of C6orf191. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which is upstream of several growth and survival pathways. If C6orf191 is involved in a pathway downstream of mTOR, its inhibition by rapamycin would lead to decreased functionality of the protein. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. By blocking MEK, PD98059 prevents the activation of ERK and subsequently could decrease the activity of C6orf191 if it is regulated by the MAPK pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Similar to PD98059, U0126 is a selective inhibitor of MEK1/2, leading to a reduction in ERK pathway signaling. If C6orf191 requires ERK activity for its function, U0126 would inhibit its activity. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB203580 specifically inhibits p38 MAPK. If the p38 MAPK pathway regulates C6orf191, inhibition by SB203580 would result in decreased activity of the protein. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. Inhibition of JNK signaling could impede cellular processes that are necessary for C6orf191 function, thus inhibiting the protein's activity if it relies on JNK signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family kinases. C6orf191, if dependent on Src kinase signaling for activation, would have reduced activity in the presence of PP2. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor, which includes Src family kinases. If C6orf191's function is contingent upon tyrosine kinase signaling, dasatinib would inhibit its activity. | ||||||